specification of eligibility criteria; random allocation; concealed allocation; prognostic similarity at baseline; participant, therapist and assessor blinding; greater than 85% follow-up of at least one key outcome; intention to treat analysis; between-group statistical comparison for at least one key outcome; and point estimates and measures of variability provided for at least one key outcome. The studies were given a score up to a maximum of 11. The authors report a method for assessing validity but do not state how many of the reviewers performed the assessment.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction.
The data were extracted into tables under the following headings: study design, number of groups, patient numbers, age range, motor types, severity at baseline, length of follow-up, loss to follow-up, interventions, outcome measures, complications, main result, treatment effect, and size of treatment effect. Where possible, the effect size was calculated for each of the RCTs.
Methods of synthesis
How were the studies combined? The studies were combined statistically. For continuous data, both the observed differences in means and the standardised differences in means (effect sizes) were used. A fixed-effect model was used to combine the data, and the treatment effect between groups was reported as a mean difference (see Other Publications of Related Interest no.2). Tests of overall effect for all of the studies were computed using a Z-score as the ratio of overall effect to its standard error, and this was compared with the normal distribution.
How were differences between studies investigated?
Heterogeneity was investigated using chi-squared analyses.
Results of the review
Sixty-one prospective studies were eligible for inclusion. Of these, 5 were RCTs and the design of the remaining studies was unclear.
Methodological quality of the 5 RCTs: 4 of the 5 studies were of moderate to high quality (PEDro scale: greater than 6 out of 11).
Three RCTs that used the same primary outcome measure, the Quality of Upper Extremity Skills Test, were analysed for treatment effects between groups using mean difference scores with 95% confidence intervals (CIs). A metaanalysis of the 3 studies was not undertaken, as they had sufficiently different treatment comparisons and did not incorporate untreated control groups. The following treatment comparisons were made.
Casting versus no casting: the standardised mean difference (SMD) was 0.17 (95% CI: -0.48, 0.81).
Intensive versus regular occupational therapy: the SMD was -0.02 (95% CI: -0.67, 0.63).
Intensive neurodevelopmental therapy and cast versus regular occupational therapy alone: the SMD was -0.15 (95% CI: -0.71, 0.40).
BTX-A and occupational therapy alone versus occupational alone at 6 months: the SMD was 0.40 (95% CI: -0.33, 1.12).
BTX-A and occupational therapy alone versus occupational therapy alone at 1 month: the SMD was 1.02 (95% CI: 0.25, 1.78).
One RCT, of BTX-A versus placebo, was not used as the authors could not calculate the treatment effect size.
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